ClinicalTrials.gg
CompletedNCT00000994Updated Nov 4, 2021

A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

A Phase 3 interventional study of Zidovudine in HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 22 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-04.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's title name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies testing zidovudine in Acquired Immunodeficiency Syndrome — none open to participants now, none under way, none of them phase 3. Zidovudine · Acquired Immunodeficiency Syndrome.

Enrollment
31st of 80
240 · median 98
Phase 3
19 of 98
none open now
Registered
1st of 98
by date
Lead sponsor
58 of 98
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 98 studies testing zidovudine in Acquired Immunodeficiency Syndrome, this one is the 31st largest by enrollment of the 80 interventional ones that give a count, is one of 19 in phase 3, and was the 1st registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 98 studies testing zidovudine in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

About zidovudine

Zidovudine: first FDA approval 1987 (RETROVIR), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 98 studies testing zidovudine in Acquired Immunodeficiency Syndrome as a file.
02

Study summary

To determine whether taking zidovudine (AZT) will change the natural course of HIV infection in patients with AIDS-associated Kaposi's sarcoma (KS) and whether administering AZT at a similar dose but at different intervals will reduce toxicity in a more manageable treatment plan.

Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent. AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether AZT therapy will delay the development of opportunistic infections and/or KS lesions.

Read the detailed description

Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent. AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether AZT therapy will delay the development of opportunistic infections and/or KS lesions.

Patients are divided into two treatment groups, the first receiving AZT for 5 doses a day, and the second receiving AZT for 3 doses per day. A placebo group is divided into two to match the two treatment groups. Study patients are stratified according to whether they have (a) 10 or fewer cutaneous lesions without oral lesions or (b) more extensive cutaneous lesions or oral lesions. Patients are seen on an outpatient basis weekly for the first 2 months, every other week for the next 2 months, and monthly thereafter.

03

Conditions studied

  • HIV Infections

Keywords

  • AIDS-Related Opportunistic Infections
  • Sarcoma, Kaposi
  • Acquired Immunodeficiency Syndrome
  • Zidovudine
04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 240 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Acute treatment for mucocutaneous candidiasis, localized cutaneous herpes simplex, or localized or disseminated zoster infections.

Concurrent Treatment:

Allowed:

  • Blood transfusion for treatment of Grade 3 toxicity if the patient's cardiovascular status is compromised or if the hemoglobin fails to show signs of recovery following withdrawal from the study drug. Toxicity grades according to NIAID Recommendations for Grading Acute and Subacute Toxic Effects (Adults).

Patients must have:

  • -related, -proven Kaposi's sarcoma mucocutaneous lesions without constitutional symptoms.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions will be excluded:

  • Symptomatic, visceral Kaposi's sarcoma.
  • Lymphedema.
  • neurologic disease as determined by a standard neurologic examination and neuropsychological questionnaire.

Concurrent Medication:

Excluded:

  • Aspirin or acetaminophen on a regular basis or for longer than 72 hours without approval of investigator.
  • Cimetidine.
  • Flurazepam.
  • Indomethacin.
  • Ranitidine.
  • Probenecid.
  • Drugs causing anemia, neutropenia, or significant risk of nephrotoxicity.
  • Prophylaxis or chronic suppression of herpes simplex.
  • Treatment of herpes simplex virus cutaneous disease more often than once a month for 5 - 7 days.

Concurrent Treatment:

Excluded:

  • Radiation therapy for treatment of Kaposi's sarcoma lesions.

The following patients will be excluded from the study:

  • Patients with a history of any AIDS-defining opportunistic infection.
  • Patients with any of the following constitutional symptoms with no etiology established:
  • Temperature more than 38 degrees and/or drenching night sweats for more than 1 month; watery diarrhea for 2 or more weeks; weight loss of more than 10 percent.
  • Patients with a history of other systemic or lymphomas.

Prior Medication:

Excluded:

  • Systemic antineoplastic chemotherapy.
  • Zidovudine (AZT).
  • Excluded within 30 days of study entry:
  • Antiretroviral agents.
  • Immunomodulating agents.
  • Prophylaxis for Pneumocystis carinii pneumonia.
  • Prophylaxis for herpes simplex virus infections.
  • Any other experimental therapy.

Prior Treatment:

Excluded within 30 days of study entry:

  • Any experimental therapy.
  • Active substance abuse.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
Enrollment
240 participants

Interventions

07

Study locations

22 sites
  • Los Angeles County - USC Med Ctr
    Los Angeles, California 90033, United States
  • UCLA CARE Ctr
    Los Angeles, California 90095, United States
  • Univ of California / San Diego Treatment Ctr
    San Diego, California 921036325, United States
  • San Francisco AIDS Clinic / San Francisco Gen Hosp
    San Francisco, California 941102859, United States
  • Stanford at Kaiser / Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • Stanford Univ School of Medicine
    Stanford, California 94305, United States
  • Charity Hosp / Tulane Univ Med School
    New Orleans, Louisiana 70112, United States
  • Louisiana State Univ Med Ctr / Tulane Med School
    New Orleans, Louisiana 70112, United States
  • Tulane Univ School of Medicine
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hosp
    Baltimore, Maryland 21287, United States
  • Harvard (Massachusetts Gen Hosp)
    Boston, Massachusetts 02114, United States
  • Univ of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Bronx Veterans Administration / Mount Sinai Hosp
    Bronx, New York 10468, United States
  • SUNY / Erie County Med Ctr at Buffalo
    Buffalo, New York 14215, United States
  • City Hosp Ctr at Elmhurst / Mount Sinai Hosp
    Elmhurst, New York 11373, United States
  • Beth Israel Med Ctr / Peter Krueger Clinic
    New York, New York 10003, United States
  • Bellevue Hosp / New York Univ Med Ctr
    New York, New York 10016, United States
  • Mem Sloan - Kettering Cancer Ctr
    New York, New York 10021, United States
  • Mount Sinai Med Ctr
    New York, New York 10029, United States
  • Univ of Rochester Medical Center
    Rochester, New York 14642, United States
  • SUNY / State Univ of New York
    Syracuse, New York 13210, United States
  • Duke Univ Med Ctr
    Durham, North Carolina 27710, United States
08

References and documents

Publications

  • Chaisson RE, Fuchs E, Stanton DL, Quinn TC, Hendricksen C, Bartlett JG, Farzadegan H. Racial heterogeneity of HIV antigenemia in people with HIV infection. AIDS. 1991 Feb;5(2):177-80. doi: 10.1097/00002030-199102000-00007. PubMed 1903261 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00000994
Responsible party
Sponsor
First posted
Aug 31, 2001
Completion
May 1990
Last update
Nov 4, 2021

Study contacts

Valentine FT
study chair
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zidovudine

Start the discussion